Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in patients with unresectable stage III/IV NSCLC with an inadequate response to ICI. jitc.bmj.com/content/14/9...
jitc.bmj.com
Prolonged survival after systemic immune reactivation by aglatimagene besadenovec plus valacyclovir in patients with unresectable stage III/IV NSCLC with an inadequate response to ICI
Background Patients with advanced non-small cell lung cancer who progress on immune checkpoint inhibitors (ICIs) face limited options and poor survival. Aglatimagene besadenovec (CAN-2409), a replicat...